← All Immucell CORP /DE/ filings

Immucell CORP /DE/ 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
ICCC
Immucell CORP /DE/
10-K/A: ImmuCell Corporation Updates 2025 Stock Option Plan
ImmuCell Corporation has refiled its 2025 Stock Option and Incentive Plan, detailing its purpose, administration, eligibility, and provisions for stock options.
NASDAQ
ICCC
Immucell CORP /DE/
10-K: ImmuCell Reports Increased Sales, Awaits FDA Decision on Re-Tain
ImmuCell Corporation's 10-K filing reveals a significant increase in First Defense product sales and provides updates on the regulatory pathway for Re-Tain, its novel mastitis treatment.
NASDAQ
ICCC
Immucell CORP /DE/
10-K: ImmuCell Corporation Reports Full Year 2023 Results, Navigates Production Challenges While Advancing Re-Tain
ImmuCell Corporation's annual report details a year of production setbacks and strategic investments, while highlighting progress in the development of Re-Tain.